Disease · MONDO_0016695

oligodendroglioma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. oligodendroglioma. Diseases, record MONDO_0016695. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016695

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: oligodendroglioma; Open Targets
Open Targets ID: MONDO_0016695; Open Targets
Other names: WHO grade II oligodendroglial neoplasm, WHO grade II oligodendroglial tumor, WHO grade II oligodendroglial tumour, well differentiated oligodendroglial tumor, well differentiated oligodendroglial tumour, well differentiated oligodendroglioma; Open Targets
Disease Ontology: DOID:3181; Disease Ontology
MeSH: D009837; MeSH
NCI Thesaurus: C3288; NCI Thesaurus
Orphanet: ORPHA:251627; Orphanet
Highest stage of its drugs: Approval, for 2 of its 29 drugs, from EMA Human Drugs, FDA and PMDA; Open Targets

Drugs29

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
VORASIDENIB	CHEMBL4279047	Small molecule	Approval	EMA Human Drugs and FDA	4	2	2	Drugs and targets
PROCARBAZINE HYDROCHLORIDE	CHEMBL1200410	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
TEMOZOLOMIDE	CHEMBL810	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
LOMUSTINE	CHEMBL514	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
PROCARBAZINE	CHEMBL1321	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
SAFUSIDENIB	CHEMBL4651002	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VINCRISTINE	CHEMBL90555	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
SARGRAMOSTIM	CHEMBL1201670	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 29

See all 29 drugs

Targets43

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CD3D	T cell surface glycoprotein CD3	2	T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 inhibitor	Phase 2	https://conductscience.org/library/genes/915	Drugs and targets
CD3E	T cell surface glycoprotein CD3	2	T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 inhibitor	Phase 2	https://conductscience.org/library/genes/916	Drugs and targets
CD3G	T cell surface glycoprotein CD3	2	T cell surface glycoprotein CD3 binding agent; T cell surface glycoprotein CD3 inhibitor	Phase 2	https://conductscience.org/library/genes/917	Drugs and targets
CDK4	Cyclin-dependent kinase 4	2	Cyclin-dependent kinase 4 inhibitor; Cyclin-dependent kinase 4/cyclin D1 inhibitor	Phase 2	https://conductscience.org/library/genes/1019	Drugs and targets
CDK6	CDK6/cyclin D1	2	CDK6/cyclin D1 inhibitor; Cyclin-dependent kinase 6 inhibitor	Phase 2	https://conductscience.org/library/genes/1021	Drugs and targets
IDH1	IDH1/IDH2	2	IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor	Approval	https://conductscience.org/library/genes/3417	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets

1 to 10 of 43

See all 43 targets

Trials23

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00049127	Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor	Phase 1/2	64	2014-10-06	Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma, Adult Oligodendroglioma, Recurrent Adult Brain Neoplasm	IMATINIB MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT02530320	Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved	Phase 2	34	2024-11-22	Oligodendroglioma, Oligoastrocytoma	PALBOCICLIB	Its record names the disease	ClinicalTrials.gov
NCT05331521	A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).	Phase 3	406		Oligodendroglioma	LOMUSTINE, PROCARBAZINE, TEMOZOLOMIDE, VINCRISTINE	Its record names the disease	ClinicalTrials.gov
NCT05303519	SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)	Phase 3	365		Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, IDH-Mutant, Grade 2, Oligodendroglioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted	SAFUSIDENIB	Its record names the disease	ClinicalTrials.gov
NCT05512325	Study on Gene Evolution in Glioma Under Stress Therapy		100		Genetic Change	BEVACIZUMAB, TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT02567539	Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma	Not applicable	88		Recurrent High Grade Glioma	TEMOZOLOMIDE	Its record names the disease	ClinicalTrials.gov
NCT05512351	Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma	Phase 2	80		Oligodendroglioma	BEVACIZUMAB, SINTILIMAB	Its record names the disease	ClinicalTrials.gov
NCT03893903	AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma	Phase 1	69		Malignant Glioma	AVELUMAB	Its record names the disease	ClinicalTrials.gov
NCT06969352	A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)	Not applicable	62		Gliomas	VORASIDENIB	Its record names the disease	ClinicalTrials.gov
NCT00004024	Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma	Phase 2	60		Brain and Central Nervous System Tumors	ALDESLEUKIN, MUROMONAB-CD3, SARGRAMOSTIM	Its record names the disease	ClinicalTrials.gov

1 to 10 of 23

See all 23 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38855053	RESULT	1	PubMed
26118437	RESULT	1	PubMed
25761491	RESULT	1	PubMed
16817692	RESULT	1	PubMed
14670747	RESULT	1	PubMed
12525516	RESULT	1	PubMed
37649695	DERIVED	1	PubMed
37533228	DERIVED	1	PubMed
35692047	DERIVED	1	PubMed
35599302	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016695

GET https://conductscience.org/api/diseases/v1/MONDO_0016695/drugs?page=2

API reference For AI assistants